AstraZeneca (AZNCF) News Today $134.22 +2.91 (+2.22%) As of 04/15/2025 03:24 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartDividendFinancialsHeadlinesOwnershipSEC FilingsShort InterestBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period AstraZeneca rallies Monday, outperforms marketApril 14 at 12:40 PM | marketwatch.comAstraZeneca’s oral breast cancer drug Truqap greenlit for NHS useApril 12, 2025 | msn.comBernstein Sticks to Its Buy Rating for AstraZeneca (AZN)April 9, 2025 | markets.businessinsider.comAstraZeneca (LSE:AZN) Gains EU Approval For Breast Cancer Treatment DATROWAYApril 9, 2025 | uk.finance.yahoo.comDaiichi Sankyo and AstraZeneca secure EU approval for DatrowayApril 9, 2025 | lse.co.ukAstraZeneca’s camizestrant gains momentum, but questions remain as first-line therapyApril 8, 2025 | finance.yahoo.comAstraZeneca’s AZD0780 Shows Promising Results in Cholesterol-Lowering Clinical TrialApril 7, 2025 | msn.comAstraZeneca slides Monday, underperforms marketApril 7, 2025 | marketwatch.comEC approves AstraZeneca’s Imfinzi combo for NSCLCApril 7, 2025 | finance.yahoo.comAstraZeneca gets EU approval for cancer treatments Enhertu and ImfinziApril 4, 2025 | lse.co.ukAstraZeneca (AZN) Receives a Buy from UBSApril 1, 2025 | markets.businessinsider.comAstraZeneca’s AZD0780 cuts LDL-C by 50% in Phase IIb trialApril 1, 2025 | finance.yahoo.comFDA approves AstraZeneca’s Imfinzi combo for bladder cancerApril 1, 2025 | finance.yahoo.comAstraZeneca's Muscle-Invasive Bladder Cancer Treatment Gets FDA ApprovalMarch 31, 2025 | marketwatch.comAstraZeneca’s Calquence recommended for approval in EU for treatment of MCLMarch 31, 2025 | markets.businessinsider.comAstraZeneca’s Imfinzi approved in US for treatment of adults with MIBCMarch 31, 2025 | markets.businessinsider.comAstraZeneca’s potential blockbuster pill halves high cholesterolMarch 31, 2025 | detroitnews.comHarbour BioMed Shares Soar on News of AstraZeneca CollaborationMarch 24, 2025 | marketwatch.comAstraZeneca to invest $2.5bn in R&D centre in ChinaMarch 24, 2025 | finance.yahoo.comAstraZeneca to invest $2.5 billion in Beijing hub as it seeks to move on from China probesMarch 22, 2025 | msn.comAstraZeneca to invest $2.5 billion in Beijing hub as it looks beyond Chinese tax probeMarch 22, 2025 | msn.comAstraZeneca to invest USD2.5 billion in new Beijing strategic centreMarch 21, 2025 | lse.co.ukAstraZeneca’s $1bn hypoparathyroidism drug achieves success at Phase IIIMarch 18, 2025 | finance.yahoo.comAstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy PortfolioMarch 18, 2025 | msn.comAstraZeneca and Alteogen agree on ALT-B4 platform techMarch 18, 2025 | finance.yahoo.comAstraZeneca to acquire EsoBiotec for $425M upfrontMarch 17, 2025 | markets.businessinsider.comAstraZeneca boosts cancer therapies push with $1 billion EsoBiotec buyMarch 17, 2025 | msn.comAstraZeneca to buy EsoBiotec in $1 billion deal to advance cell therapy ambitionMarch 17, 2025 | msn.comAstraZeneca: A Big Pharma Blue Chip To Buy NowMarch 5, 2025 | seekingalpha.comAmgen and AstraZeneca report results from Phase III trial of Tezspire for CRSwNPMarch 3, 2025 | finance.yahoo.comAstraZeneca says Imfinzi-based perioperative regimen recommended for EU approvalMarch 3, 2025 | markets.businessinsider.comAmgen, AstraZeneca announce results from Phase 3 WAYPOINT trial on tezspireMarch 2, 2025 | markets.businessinsider.comAstraZeneca opens biomethane plant in UK to cut emissionsFebruary 27, 2025 | reuters.comAstraZeneca reports positive outcomes from breast cancer combo therapy trialFebruary 27, 2025 | finance.yahoo.comAstraZeneca data ‘positive’ for Olema’s palazestrant, says H.C. WainwrightFebruary 26, 2025 | markets.businessinsider.comAstraZeneca announces results from interim analysis of SERENA-6 Phase III trialFebruary 26, 2025 | markets.businessinsider.comAstraZeneca’s Breast Cancer Drug Shows Positive Results In Late-Stage TrialFebruary 26, 2025 | msn.comAstraZeneca receives A1 rating upgrade from Moody's, outlook stableFebruary 21, 2025 | investing.comFibroGen sells China unit to AstraZeneca for $160mFebruary 20, 2025 | finance.yahoo.comAstraZeneca boosts China presence with FibroGen's anemia drug in $160 million dealFebruary 20, 2025 | msn.comAmid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 MillionFebruary 20, 2025 | benzinga.comFDA posts observations from AstraZeneca site inspectionFebruary 20, 2025 | markets.businessinsider.comBernstein Reaffirms Their Buy Rating on AstraZeneca (AZN)February 20, 2025 | markets.businessinsider.comAstraZeneca to buy FibroGen's China unit for $160 millionFebruary 20, 2025 | msn.comAstraZeneca hit with US class action lawsuit over China regulatory probesFebruary 18, 2025 | ft.comAstraZeneca’s Imfinzi bladder cancer regimen improves survival in Phase III trialFebruary 17, 2025 | msn.comAstraZeneca: IMFINZI improved event-free survival, OS across MIBCFebruary 15, 2025 | markets.businessinsider.comAstraZeneca upgraded to Buy from Neutral at UBSFebruary 13, 2025 | markets.businessinsider.comAstraZeneca upgraded by UBS to buy on growth potentialFebruary 13, 2025 | msn.comBofA maintains Buy on AstraZeneca stock, GBP145.00 targetFebruary 12, 2025 | msn.com Remove Ads Get AstraZeneca News Delivered to You Automatically Sign up to receive the latest news and ratings for AZNCF and its competitors with MarketBeat's FREE daily newsletter. Email Address AZNCF Media Mentions By Week AZNCF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AZNCF News Sentiment▼0.060.79▲Average Medical News Sentiment AZNCF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AZNCF Articles This Week▼56▲AZNCF Articles Average Week Remove Ads Get AstraZeneca News Delivered to You Automatically Sign up to receive the latest news and ratings for AZNCF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies 4Front Ventures News Today Algernon Pharmaceuticals News Today Allstar Health Brands News Today Anew Medical News Today Arno Therapeutics News Today AVAX Technologies News Today AVVAA World Health Care Products News Today BriaCell Therapeutics News Today Cannabis Global News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:AZNCF) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryThe crypto summit Wall Street wants to stop Learn how to structure your portfolio like the top hedge funds...Crypto 101 Media | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AstraZeneca PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share AstraZeneca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AZNCF Stock Free AZNCF Stock Alerts